Vertex Pharmaceuticals (VRTX) continues to attract investor attention driven by its robust financial health and growth prospects in the biotechnology sector. Headquartered in Boston, the company focuses on transformative medicines for serious diseases, specifically targeting niche markets like cystic fibrosis, sickle cell disease, and transfusion-dependent...
Vertex Pharmaceuticals reported positive Phase 3 data for its CRISPR-based gene therapy, CASGEVY, demonstrating consistent efficacy and safety in children aged 5–11 with severe sickle cell disease and transfusion-dependent beta thalassemia. All evaluable patients met key endpoints over at least 12 months of follow-up, extending...
Vertex Inc reported first quarter 2026 earnings with revenue reaching $196.6 million, representing an 11% year-over-year increase that beat analyst estimates by $1.82 million. The transcript captures the opening remarks from Joseph Crivelli, Vice President of Investor Relations, who introduced CEO Christopher Young and CFO...
Benzinga's automated content engine reports that Michel Lagarde, a Board Member at Vertex Pharmaceuticals (NASDAQ: VRTX), executed a derivative transaction on May 5 to acquire stock options for 2,866 shares according to a Form 4 filing with the U.S. Securities and Exchange Commission. The article...
Vertex Pharmaceuticals recently announced that director Suketu Upadhyay will depart the board at the 2026 annual meeting, coinciding with a significant regulatory milestone as the US FDA approved an expanded use of ALYFTREK for cystic fibrosis patients aged six and older. This approval is viewed...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has been recognized as a top large-cap biotech pick for 2026 by Bank of America, which reiterated its buy rating and set a $598 price objective. The bank highlighted the company's cystic fibrosis franchise as capable of generating sufficient cash flow...
Vertex Pharmaceuticals announced on April 28, 2026, that director Suketu Upadhyay will not stand for re-election at the company's annual meeting. This decision follows his new appointment as the forthcoming chief financial officer of Incyte Corporation, which creates scheduling conflicts with his duties at Vertex....
Vertex Pharmaceuticals announced on April 28, 2026, that board member Suketu Upadhyay will not seek re-election at the company’s 2026 annual meeting following his appointment as chief financial officer of Incyte Corporation. The board confirmed there are no operational or policy disagreements regarding this transition,...
Vertex Pharmaceuticals Inc. (VRTX) shares closed lower on Wednesday, slipping 1.60% to $423.24 as the broader market experienced a downturn. The S&P 500 Index fell 0.04% to close at 7,135.95, while the Dow Jones Industrial Average dropped 0.57% to 48,861.81 during the trading session. Despite...
Vertex Pharmaceuticals (NASDAQ: VRTX) has been identified through a screening strategy combining fundamental strength with favorable technical patterns, targeting companies with accelerating earnings and revenue alongside solid profitability and a healthy balance sheet. Fundamentally, Vertex holds a rating of 7 out of 10 based on...
Analysts have issued conflicting ratings on three healthcare companies, with Phathom Pharmaceuticals (PHAT), Pfizer (PFE), and Guardant Health (GH) receiving mixed sentiment from the Street. Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Phathom Pharmaceuticals today, noting that shares closed at $11.28 last Tuesday....
Vertex Pharmaceuticals is scheduled to report its first-quarter 2026 earnings on May 4, following the market close. Analysts at Zacks have pegged the consensus revenue estimate at $2.98 billion and earnings per share at $4.20. Revenue growth is expected to be primarily driven by strong...
Vertex Pharmaceuticals is preparing to release its first-quarter 2026 financial results on May 4, following the market close. Analysts anticipate revenue of approximately $2.98 billion and earnings per share of $4.20. The primary driver for these figures is expected to be continued strong demand for...
Vertex Pharmaceuticals (VRTX) is scheduled to report its first-quarter 2026 financial results after market close on May 4, with the Zacks Consensus Estimate pegging revenues at $2.98 billion and earnings at $4.20 per share. The company's revenue performance will likely be heavily influenced by sales...
Vertex Pharmaceuticals (VRTX) has experienced recent share price weakness, with its stock down 1% over the past day and 3% over the last week. Over the medium to long term, the momentum shows mixed performance, featuring a 90-day decline of 10.2% and a one-year total...
Vertex Pharmaceuticals (VRTX) is poised to report quarterly earnings for the period ended March 2026 on May 4, with market expectations set for a year-over-year increase in both revenues and earnings. Analysts project quarterly earnings of $4.20 per share, representing a 3.5% rise from the...
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) remains a leading biotechnology company specializing in transformative treatments for serious genetic disorders, most notably cystic fibrosis and sickle cell disease. As of the latest data, the company's market capitalization stands at $109.5 billion, with shares currently trading at $430.5...
Vertex Pharmaceuticals Inc. (VRTX) shares experienced a modest decline of 1.11%, closing at $430.29 on Friday, April 24, 2026. This move occurred in an overall mixed trading environment for the broader market, where the S&P 500 Index rose 0.80% to reach 7,165.08 and the Dow...
Vertex Pharmaceuticals (VRTX) shares declined 1.06% to close at $430.50, underperforming the broader market as the S&P 500 rose 0.8% and the Nasdaq gained 1.63%. Over the previous month, VRTX lost 4.11%, trailing the Medical sector's slight loss of 0.32% while significantly lagging the S&P...
Vertex Pharmaceuticals (NASDAQ: VRTX) continues to solidify its position as a leader in cystic fibrosis (CF) while actively pursuing strategic diversification into pain, renal disease, and gene therapies. The company's CF franchise remains robust, driven by the launch of ALYFTREK, geographic expansion efforts, and increased...
